| Shirish C Patrawalla, MD | |
|
264 Boyden Ave, Maplewood, NJ 07040 | |
| (973) 763-4120 | |
| (973) 763-1713 |
| Full Name | Shirish C Patrawalla |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 264 Boyden Ave, Maplewood, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245346188 | NPI | - | NPPES |
| 2062305 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 27791 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shirish C Patrawalla, MD 264 Boyden Ave, Maplewood, NJ 07040 Ph: (973) 763-4120 | Shirish C Patrawalla, MD 264 Boyden Ave, Maplewood, NJ 07040 Ph: (973) 763-4120 |
News Archive
New research conducted in a cancer center in a state that had legalized the use of recreational and medicinal cannabis shown that about one-fourth of surveyed cancer patients used cannabis in the previous year, mostly for psychological and physical symptoms. The study also indicated that legalization increased the likelihood of a rise of cannabis use among cancer patients.
Underlying conditions that increase risk of severe illness or death from COVID-19 are much more common among Black, Native American, and lower-income people in the United States.
MTBC, a unique healthcare IT company, is pleased to announce that its proprietary EHR, MTBC EMR v 5.0, is 2011/2012 compliant and was certified as a Complete EHR on February 2, 2011 by the Certification Commission for Health Information Technology (CCHIT®), an ONC Authorized Testing and Certification Body (ONC-ATCB).
Chemists have long believed that inserting nitrogen - a beneficial ingredient for making many pharmaceuticals and other biologically active molecules - into a carbon-hydrogen bond requires a trade-off between catalyst reactivity and selectivity.
TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
› Verified 4 days ago
Dr. Samuel T Duncan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2040 Millburn Ave, Suite 303, Maplewood, NJ 07040 Phone: 973-762-4996 Fax: 973-762-4955 | |
Shailender Karry Mohanrao, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2115 Millburn Ave, Suite L2, Maplewood, NJ 07040 Phone: 973-275-1322 Fax: 973-900-8917 | |
Dr. Segun V Simon, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2130 Millburn Ave, Suite C-3, Maplewood, NJ 07040 Phone: 973-996-2727 Fax: 973-763-2558 | |
Sunil Patel, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2010 Springfield Ave, Maplewood, NJ 07040 Phone: 973-275-9500 Fax: 973-275-9501 | |
Dr. Khalil Ahmed Kaid, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2168 Millburn Ave, Suite 204, Maplewood, NJ 07040 Phone: 973-762-3353 Fax: 973-762-3370 | |
Dr. Arvind K Grover, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2168 Millburn Ave, Maplewood, NJ 07040 Phone: 973-763-5765 Fax: 973-763-0505 |